Showing results (2031-2040 of 2,196) with videos related to

Sort By:
Pageof 220
Nature Medicine|March 26, 2025
Transmission dynamics of the 2022 mpox epidemic in New York CityJonathan E Pekar, Yu Wang, Jade C Wang, et al.
The Journal of Clinical Endocrinology and Metabolism|January 10, 2008
Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome EvaluationLeslee J Shaw, C Noel Bairey Merz, Ricardo Azziz, et al.
Journal of Neuro-Oncology|October 24, 2015
Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experienceBrandon S Imber, Steve E Braunstein, Fred Y Wu, et al.
NPJ Digital Medicine|August 7, 2025
Novel radiotherapy target definition using AI-driven predictions of glioblastoma recurrence from metabolic and diffusion MRINate Tran, Tracy L Luks, Yan Li, et al.
International Journal of Radiation Oncology, Biology, Physics|October 23, 2023
A Prospective Registry Study of 68Ga-DOTATATE PET/CT Incorporation Into Treatment Planning of Intracranial MeningiomasHaley K Perlow, Ansel P Nalin, Demond Handley, et al.
The Journal of Biological Chemistry|April 22, 2005
The adipocyte as an important target cell for Trypanosoma cruzi infectionTerry P Combs, Nagajyothi, Shankar Mukherjee, et al.
Journal of Neurosurgery. Pediatrics|April 11, 2020
Bringing high-grade arteriovenous malformations under control: clinical outcomes following multimodality treatment in childrenEthan A Winkler, Alex Lu, Ramin A Morshed, et al.
Blood|May 22, 2023
Silent cerebral infarction during immune TTP remission: prevalence, predictors, and impact on cognitionShruti Chaturvedi, Jia Yu, Jenna Brown, et al.
Cell Reports|March 29, 2018
Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma ProliferationHarish N Vasudevan, Steve E Braunstein, Joanna J Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2020
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition ProgressionStephanie Lheureux, Ana Oaknin, Swati Garg, et al.
Pageof 220